Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/12034754231223148 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1).
J Am Acad Dermatol
November 2024
Sun Pharmaceutical Industries, Inc., Lexington, Massachusetts.
Article Synopsis
- Alopecia areata (AA) is a hair loss disorder that significantly affects quality of life, and studies have shown that the JAK inhibitor deuruxolitinib can promote hair regrowth in affected individuals.
- A Phase 3 trial tested deuruxolitinib in adults aged 18-65 with severe hair loss, finding that a significant percentage of patients experienced notable improvements in hair regrowth compared to a placebo.
- Although the treatment was generally well-tolerated with mostly mild side effects, further research is needed to assess long-term safety and the effects of stopping the treatment.
Prevalence of omalizumab-resistant chronic urticaria and real-world effectiveness of dupilumab in patients with omalizumab-refractory chronic urticaria: a single-centre experience.
Clin Exp Dermatol
September 2024
Division of Dermatology, McGill University, Montreal, QC, Canada.
Chronic urticaria (CU) is characterized by weals (hives) angio-oedema (or both) that last for ≥ 6 weeks, with chronic spontaneous urticaria (CSU) being the most common subtype. Patients with omalizumab-refractory CSU represent an unmet clinical need. In this study, we aimed to assess the prevalence and predictors of omalizumab failure in a large cohort of patients with CU and assess the effectiveness of dupilumab for omalizumab-refractory CU.
View Article and Find Full Text PDFSpontaneous resolution of eruptive papules following ablative laser resurfacing-Case report and review of laser-associated eruptive keratoacanthomas.
J Cosmet Dermatol
June 2024
AboutSkin Dermatology and Derm Surgery, Greenwood Village, Colorado, USA.
Background: Keratoacanthomas (KAs) following laser treatment are a rare, but well-described entity.
Aim: Herein, we describe a case of eruptive keratoacanthoma (KA) following laser resurfacing treatment and aim to better characterize laser-associated KAs.
Methods: A literature search was performed on PubMed reviewing laser-associated KAs including various characteristics: epidemiology, history of skin cancer, location, and number, type of laser, as well as the management and outcome.
Montreal Derm FilEZ: Validation of an Online Dermatology Educational Platform for Medical Dermatology Residents, a Randomized Control Trial.
J Cutan Med Surg
April 2024
Division of Dermatology, Department of Medicine, McGill University, Montréal, QC, Canada.
Comparative efficacy of ligelizumab versus omalizumab in chronic spontaneous urticaria.
Lancet
January 2024
Division of Dermatology, Department of Medicine, McGill University, Montréal, QC, Canada; McGill University Health Centre, Montréal, QC H3G 1A4, Canada. Electronic address:
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!